Literature DB >> 11102592

A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring.

E Weisberg1, I S Fraser, J Baker, D Archer, B M Landgren, S Killick, P Soutter, T Krause, C d'Arcangues.   

Abstract

Little is known about the effects of contraceptive vaginal rings on the vaginal surface epithelium, although most studies have not demonstrated any significant deleterious effect. However, one study found that some medium-to-long-term levonorgestrel-releasing ring users developed chronic erythematous and ulcerative lesions in the posterior vaginal fornix. Subsequently, this ring was completely redesigned (IVR-2) with different dimensions and much greater flexibility. The first version of IVR-2 was designed as a placebo ring to explore effects on the vagina and cervix without addition of a progestogen. One-hundred-sixty-six healthy sexually active women volunteers were recruited in four centers and randomly assigned for 6 months to either placebo ring use or control (non-use) using a predetermined randomization code generated by WHO in a 2:1 ratio. Careful inspections of the vaginal and cervical epithelium were performed with a colposcope at admission and at 2-month intervals. No clinically significant lesions were detected in any center either among ring users or controls. However, a number of minor changes in appearance of the vaginal and cervical epithelium (erythema, petechiae, ecchymosis, and minor aceto-white changes) were described from the Sydney Center, some of which were present on admission and some of which were found on subsequent examination. Ten of eleven "red" changes on the cervix and vagina were noted in IVR-2 users, and only one in the controls, suggesting a contribution by the IVR-2 to minor epithelial surface changes. Five of ten resolved completely with continued ring use. There was no correlation in this study between epithelial changes and cigarette smoking or frequency of intercourse in the 14 days prior to colposcopic examination but a significant relationship between tampon use in the last 7 days and all epithelial changes (p = 0.05) and especially red changes (p = 0. 027) was noted. Red changes were significantly less likely to be found among condom users (p = 0.007). The IVR-2 placebo ring did not produce clinically significant changes in the vaginal epithelium and cervical mucosa and a carefully controlled and randomized study should be considered to compare the epithelial appearances in women using a placebo IVR-2 and one releasing 20 microg levonorgestrel.

Entities:  

Mesh:

Year:  2000        PMID: 11102592     DOI: 10.1016/s0010-7824(00)00137-2

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine.

Authors:  Manpreet Kaur; Kavita M Gupta; Azadeh E Poursaid; Prasoona Karra; Alamelu Mahalingam; Hyder A Aliyar; Patrick F Kiser
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

2.  A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.

Authors:  Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 3.  Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Jennifer A Hurlburt; Gustavo F Doncel
Journal:  Int J Womens Health       Date:  2013-10-21

4.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

5.  HIV-Exposed Seronegative Sex Workers Express Low T-Cell Activation and an Intact Ectocervical Tissue Microenvironment.

Authors:  Maria Röhl; Annelie Tjernlund; Julie Lajoie; Gabriella Edfeldt; Frideborg Bradley; Sofia Bergström; Vilde Kaldhusdal; Alexandra Åhlberg; Anna Månberg; Kenneth Omollo; Geneviève Boily-Larouche; Muhammad Asghar; Douglas S Kwon; Julius Oyugi; Joshua Kimani; Peter Nilsson; Keith R Fowke; Kristina Broliden
Journal:  Vaccines (Basel)       Date:  2021-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.